Human Immunodeficiency Virus

Medicines in the Human Immunodeficiency Virus category are antiviral drugs used to control HIV infection by reducing the amount of virus circulating in the body and helping preserve immune system function. These therapies do not cure HIV but are designed to suppress viral replication, slow disease progression, and reduce the risk of complications associated with immune system damage. The category covers a range of pharmaceutical approaches developed specifically to target different stages of the viral lifecycle.

Common uses for this class of medicines include initial treatment of people diagnosed with HIV, ongoing maintenance to keep the virus suppressed, and specific preventive applications in particular situations. Some drugs are formulated for daily oral use, while others are formulated for short-term or event-based prevention strategies or long-acting injectable administration. Choice of regimen depends on clinical goals such as rapid viral suppression, prevention of transmission, management of coexisting conditions, and considerations of convenience and tolerability.

Medications in this area fall into several well-established groups that act by different mechanisms. Nucleoside or nucleotide reverse transcriptase inhibitors (often abbreviated NRTIs) block an early step in viral replication and include medicines like lamivudine, known commercially as Epivir; a version labeled Epivir HBV contains the same active ingredient as treatment for hepatitis B infection. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz (Sustiva) act at a related step through a different molecular mechanism. Protease inhibitors, exemplified by lopinavir/ritonavir combinations (commonly referenced under names such as Kaletra), interfere with a later stage of virus assembly. Newer classes, including integrase inhibitors and entry inhibitors, are also commonly used as part of combination therapy.

Treatment strategies typically rely on combining medicines from different classes to achieve stronger and more durable viral suppression and to reduce the likelihood of resistance developing. Fixed-dose combination pills that merge two or more active agents into a single tablet are widely available and can simplify dosing schedules. Pharmacokinetic enhancers or “boosters” are sometimes used alongside protease inhibitors to increase drug levels. Long-acting formulations and injectable preparations have been developed in recent years to address adherence and convenience for some people.

Safety and monitoring considerations are an important part of managing therapy with these drugs. Adverse effects vary by agent and may include gastrointestinal symptoms, changes in cholesterol or blood sugar, neuropsychiatric effects, or effects on liver and kidney function. Many antiretroviral medicines interact with other prescription drugs, over-the-counter products, and herbal supplements because of shared metabolic pathways, which can affect effectiveness or increase side effects. Coexisting health conditions, such as hepatitis B or pregnancy, can influence medication selection and require attention to specific drug properties.

When people evaluate options in this category they commonly consider factors such as dosing frequency, pill burden, potential side effect profiles, history of prior antiretroviral use or resistance, interactions with other medications, and any co-infections or other medical conditions that might affect choice. Practical concerns like formulation type, storage requirements, availability of combination products, and continuity of therapy also play a role. Clinical guidance and testing historically inform selection and adjustment of regimens, and innovations in formulation and delivery continue to expand options available to people living with or at risk of HIV.